Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560455 | 0.88 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL8566361 | 0.87 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL8566357 | 0.87 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL9208843 | 0.87 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL8661598 | 0.83 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL8600536 | 0.82 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL8567422 | 0.82 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL8563064 | 0.81 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL8563050 | 0.79 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL8565102 | 0.77 | AGTR1 (0.61) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0649424-B1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | KNOLL AG (DE) | 1998-10-07 | — | — | EP | claimed |
| WO-1994001436-A1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1994-01-20 | — | — | WO | claimed |
| EP-0649424-B1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | KNOLL AG (DE) | 1998-10-07 | — | — | EP | disclosed |
| US-5627191-A | Therapeutic agents | THE BOOTS COMPANY PLC (GB) | 1997-05-06 | — | — | US | disclosed |
| WO-1994001436-A1 | DIOXCYCLOBUTENE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1994-01-20 | — | — | WO | disclosed |